Cysteinyl leukotriene receptor 1 (cysLT1R) regulates osteoclast differentiation and bone resorption
Source abstract
Abstract
Excessive bone resorption induced by abnormal osteoclast differentiation has been associated with bone microstructure damage and bone-associated disorders, including osteoporosis. Here, we investigated the physiological roles of the type 1 cysteinyl leukotriene receptor (cysLTR-1) and the pharmacological functions of the specific cysLTR-1 antagonist montelukast on M-CSF- and RANKL-induced osteoclast differentiation. We showed that cysLTR-1 but not cysLTR-2 is expressed in osteoclast precursor cells: mouse bone marrow-derived macrophages (BMMs). We also found that treatment with M-CSF and RANKL significantly increased expression of cysLTR-1. Overexpression of cysLTR-1 promoted osteoclast differentiation of BMMs by increasing NFATc1 and TRAP. In contrast, treatment with montelukast prevented M-CSF- and RANKL-induced osteoclast differentiation of BMMs. Mechanically, our findings demonstrate that montelukast treatment attenuated activation of the ERK1/2, p38, JNK and NF-κB signalling pathways. Additionally, we reported that montelukast treatment ameliorated the generation of ROS and calcium signalling. Importantly, the co-immunoprecipitation assay displayed that montelukast treatment prevented the interaction of RANK and TRAF6. Finally, in vivo experiments indicated that montelukast rescued the reduction of bone volume as well as trabecular number in an ovariectomy mouse model.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bone Metabolism and Diseases · Bone health and treatments · TGF-β signaling in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Reparative and Reconstructive Surgery, Linyi People’s Hospital
Department of Stomatology, Linyi People’s Hospital
References (32)
Show source-provided references
1. 10.1002/jbmr.154710.1002/jbmr.1547 ↗
2. 10.1016/S1534-5807(02)00157-010.1016/S1534-5807(02)00157-0 ↗
3. 10.1146/annurev.immunol.24.021605.09064610.1146/annurev.immunol.24.021605.090646 ↗
4. 10.1038/s41598-017-11246-510.1038/s41598-017-11246-5 ↗
5. 10.1002/jcb.1050310.1002/jcb.10503 ↗
6. 10.1038/nri206210.1038/nri2062 ↗
7. 10.1177/002203451559259210.1177/0022034515592592 ↗
8. 10.3390/ijms1812263510.3390/ijms18122635 ↗
9. 10.1038/ni0208-11310.1038/ni0208-113 ↗
10. 10.1016/j.alit.2014.09.00110.1016/j.alit.2014.09.001 ↗
11. 10.4049/jimmunol.176.7.444010.4049/jimmunol.176.7.4440 ↗
12. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127:1312–1326.
13. 10.1093/qjmed/hci02410.1093/qjmed/hci024 ↗
14. 10.1164/rccm.200501-088OC10.1164/rccm.200501-088OC ↗
15. 10.1056/NEJMra07137110.1056/NEJMra071371 ↗
16. 10.1111/j.2042-7158.2010.01238.x10.1111/j.2042-7158.2010.01238.x ↗
17. 10.1038/nm.186010.1038/nm.1860 ↗
18. 10.1016/j.bone.2006.02.06010.1016/j.bone.2006.02.060 ↗
19. 10.1038/nature1100010.1038/nature11000 ↗
20. 10.1016/j.bbrc.2010.02.01310.1016/j.bbrc.2010.02.013 ↗
21. 10.1159/00036638710.1159/000366387 ↗
22. 10.1038/nature0165810.1038/nature01658 ↗
23. 10.14348/molcells.2017.022510.14348/molcells.2017.0225 ↗
24. 10.1016/S0006-291X(03)00695-810.1016/S0006-291X(03)00695-8 ↗
25. 10.3389/fimmu.2014.0051110.3389/fimmu.2014.00511 ↗
26. 10.1038/sj.embor.740034510.1038/sj.embor.7400345 ↗
27. 10.4049/jimmunol.080152510.4049/jimmunol.0801525 ↗
28. 10.1074/jbc.M109.05155710.1074/jbc.M109.051557 ↗
29. 10.3109/21691401.2014.92645610.3109/21691401.2014.926456 ↗
30. 10.1182/blood-2004-09-366210.1182/blood-2004-09-3662 ↗
31. Guo X, Wei S, Lu M, et al. RNA-Seq investigation and in vivo study the effect of strontium ranelate on ovariectomized rat via the involvement of ROCK1. Artif Cells Nanomed Biotechnol. 2018;30:1–13.
32. Tsai MK, Lin YC, Huang MY, et al. The effects of asthma medications on reactive oxygen species production in human monocytes. J Asthma 2017;11:1–9.